In press

2025-12-03

  Ilya Pharma co-founder Professor Mia Phillipson has been elected as a member of Kungl. Ingenjörsvetenskapsakademien (IVA)

Mia’s election recognises her outstanding contributions — both in her research in hashtag#physiology founding Ilya Pharma and in hashtag#driving hashtag#innovation at the interface of science, business and healthcare. Her voice will now join IVA’s distinguished network of thinkers and doers shaping the future of Swedish industry and innovation. IVA — the world’s oldest academy of engineering sciences, which unites around 1,300 leading engineers, researchers, entrepreneurs and business leaders to advance technology, industry and sustainable societal development, see more at iva.se

2025-06-03

  Contagion Live highlights the new publication in Infectious Diseases and Therapy showing data on the dual action of ILP100

Contagion Live highlights the new publication in Infectious Diseases and Therapy showing data on the dual action of ILP100 - healing of skin and mucosal surfaces AND killing Multi- and Severely Drug Resistant bacterial pathogens isolated in Ukraine, currently spreading across Europe and globally. "Elimination of MDR bacteria by the addition of ILP100 shows that antagonistic bacteria may provide promising new treatment options in the face of the currently stagnating antimicrobial pipeline," Professor Mia Phillipson concludes.

2025-02-07

  Ilya Pharma CEO selected for Eisenhower Fellowship named after American President Dwight D. Eisenhower to promote global peace and development

The topic of the Fellowship centers on exploring the ongoing initiatives in Multi-Drug Resistant (MDR) pathogen testing, treatment and policy reform with the aim to participate to the #solution identifying and collaborating with stakeholders and discover how the companys resent research in fighting MDR microbes with therapeutic microbes in different diseases may best deliver impact to patients.

2024-11-30

  Developments of ILP100-Oral was highlighted in an Editorial by American Journal of Gastrointestinal and Liver Physiology

"The implications of this study are substantial, extending beyond immediate therapeutic benefits to broader impacts on the field of colitis treatment and potentially other inflammatory diseases. The methodology used in this study could be adapted for other inflammatory diseases by engineering L. reuteri to express different therapeutic proteins. This broadens the potential applications of this approach beyond colitis" Our asset ILP100-Oral is currently at IND stage in development with: ✅ FDA pre-IND meeting completed allowing first-line-treatment ✅ SITU-GUT clinical phase 1/2a trial developed with KOLs for ICI-induced colitis stage 1 and 2 ✅CMC and GMP synergies with ILP100-Topical already in Phase 2 clinical developments with IND cleared for pivotal study ✅ Exceptional COGs, stability in room temperature ✅ Projections of blockbuster potential ➡️ The company seeking a suitable partner to accelerate the clinical development for this asset and share the expected joys of developing ground breaking research 💊 and the expected value generated💰 💰